• Today’s consumers are increasingly moving towards online automotive transactions for increased efficiency and safety
• PowerBand Solutions continues to deploy its comprehensive virtual platform for buying and leasing automobiles online via home computers or handheld smart devices
• The company’s platform enables seamless sales transactions by including responsiveness to financing, inventory and inspections

The world is becoming more connected every day. Devices have the ability to collect and exchange data points in an ecosystem of smart devices without human involvement. Between 2015 and 2025, those data points are expected to experience a five-fold increase (http://ibn.fm/7XZOO).

This is great news for the automotive industry, and PowerBand Solutions (TSX.V: PBX) (OTCQB: PWWBF) (FRA: 1ZVA), which is emerging as the leader in online vehicle transactions using smart phones.  With more touch points, companies can better understand consumers, their needs and their buying habits. From there, messaging and processes can be increasingly customized and effective in engaging consumers. For progressive automotive companies, this improved access will create more opportunities to collect information about consumers, provide them with a more convenient purchasing experience, and drive engagement accordingly.

Disruptive fintech innovator PowerBand is leveraging the advancements in technology to drive its smart-tech-accessible platform to obtain household name status as a preferred means of buying and leasing automobiles. The platform offers a personalized online purchase journey capable of addressing any concerns that may arise between listing and sale with success rates not possible with other online services.

The automotive industry has been in a state of flux, with every aspect experiencing disruption from driverless vehicles to artificial intelligence. Customer expectations continue to become increasingly sophisticated as technological innovations progress. As more customers begin to expect the seamless digital service they receive in other retail markets, the automotive industry must adapt to remain competitive and protect profits as well as finance and insurance margins. To do so, retailers must find opportunities to leverage the digital-oriented nature of buyers and their desire for advanced technology. The automotive industry and consumers are both responding quickly to take advantage of the added convenience.

With the coronavirus continuing to surge in many areas throughout the United States, consumers are seeking online transactions in every market in order to limit face-to-face interaction. Buying a car sight-unseen sounds daunting, but today’s consumers seem to have absolutely no problem doing so. According to the ‘Digital Commerce 360 Online Vehicle Shopper 2019’ survey, conducted among 1,089 buyers, 49% are willing to purchase a new vehicle entirely online (http://ibn.fm/2Rt8i). According to Frost & Sullivan, consumers may purchase as many as 1.3 million vehicles annually online as soon as 2035 (http://ibn.fm/q3Nmq).

Even more traditional legacy manufacturers like Honda are getting on board. The auto giant recently decided to pre-sell its Limited-Edition Civic Type R “hot hatch” entirely online. The virtual order books opened up 1 p.m. and by 1:04 p.m., all 100 build slots were taken. Each reservation required a $1,000 deposit. And Honda has yet to announce the final price for the car (http://ibn.fm/wVmZ7).

PowerBand Solutions is uniquely positioned to experience this silver lining of the crisis. The company’s innovation in providing a highly effective online trading alternative attracted Texas-based D&P Holdings, Inc., one of the largest administrators of automotive warranty and insurance products in the United States. D&P made a $6 million direct investment in the company and has stated it intends to invest $10 million eventually.

“While COVID-19 has caused unexpected business delays for many of us, this crisis has reinforced our belief that PowerBand will revolutionize how consumers and dealers interact when they buy, sell, lease and trade cars and trucks,” D&P CEO John Armstrong stated in April (http://ibn.fm/FqfE3).

PowerBand’s platform digitizes not only the transfer of money, but also the financing and inventory paperwork, vehicle inspections, and auction negotiations. The streamlined platform provides a speed, ease, and cost-efficiency in automotive sales that is expected to dramatically impact the industry.

For more information, visit the company’s website at www.PowerBandSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to PWWBF are available in the company’s newsroom at http://ibn.fm/PWWBF

• Sleep apnea devices market growth also driven by the current pandemic which has made it exponentially more difficult for patients to seek treatment for their condition
• Registered with the FDA as a Specification Developer, Vivos develops and markets the first non-surgical, non-invasive and cost-effective solution for the estimated billion of people globally who suffer from OSA
• Vivos believes its proprietary system is poised to provide the most significant breakthrough in OSA treatment since CPAP

The global sleep apnea market is expanding rapidly, being expected to reach $13.24 billion by 2027, from $7.81 billion in 2019, exhibiting a CAGR of 6.8 percent. In a report titled “Sleep Apnea Devices Market Size . . .”, Fortune Business Insights notes that the rising cases of cardiovascular disorders and diabetes among the geriatric population are some of the primary causes of the surge in sleep apnea (http://ibn.fm/wlVz2). Additionally, a reduction in polysomnography, laboratory-based CPAP (Continuous Positive Airway Pressure) and bi-level therapy can cause a decline in diagnosis of new sleep apnea cases as well as exert a negative impact on the growth of the market. Moreover, the report cites NCBI data indicating a 50 percent decline in compliance rates for CPAP devices. This has created the need for alternative oral appliances to provide comfort to sleep apnea patients.

An emerging global leader in the treatment of obstructive sleep apnea (“OSA”), Vivos Therapeutics, Inc. is uniquely positioned to capitalize on this growing market and the increased demand for sleep apnea alternative solutions. The company’s proprietary Vivos System(R) is the first treatment modality for mild to moderate OSA in adults that does away with the need for lifelong interventions. The system’s treatment time is a fraction of that of its alternatives, potentially offering patients lasting relief in a matter of months, eliminating the need for surgery (http://ibn.fm/xdHWd).

The leading cause of OSA is a deficiency in the development of craniofacial anatomy. Pneumopedics  is the natural process introduced by Vivos biomimetic technology where the airway tissues are remodeled resulting in enhanced capacity over the course of treatment, which typically ranges from 18 to 24 months. Unlike many other approaches, it aims for a lasting resolution by targeting the root cause of sleep apnea.

Registered with the FDA as a Specification Developer, Vivos develops and markets a number of oral appliances. Its technology represents the first non-surgical, non-invasive and cost-effective solution for the estimated one billion people worldwide who suffer from OSA. Vivos Therapeutics believes its technology represents the most important breakthrough in OSA treatment since CPAP, which involves the use of special face or nasal masks.

The company’s oral appliances have proven to be effective in more than 15,000 patients successfully treated worldwide by approximately 1,350 trained dentists. Vivos’ vision is to provide clinicians with the tools to provide the best alternative solution to treat OSA.

For more information, visit the company’s website at www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to Vivos Therapeutics are available in the company’s newsroom at http://ibn.fm/VVOS

• The need for efficient drug procurement and delivery has never been more in demand
• Trxade Group’s unmatched supply chain trading platform represents a unique portal to speeding up drug distribution
• Such efficiencies are key to improving margins and keeping America’s independent pharmacies alive

Not in recent memory have medical services and associated support personnel been viewed as more vital to the nation. Just as indispensable, but not as visible, are the supply chain channels through which medical supplies flow, for doctors without medicines may be so handicapped as to be useless. So too would be pharmacies where the bulk of medicines are dispensed. As a result, it is crucial that these supply chain channels operate efficiently.

One company has been working specifically toward that end. Trxade Group (NASDAQ: MEDS) has developed an integrated drug procurement and delivery platform that is improving supply chain and market efficiency, speeding up distribution of drugs while also ensuring critical transparency on prices. This is good news for independent pharmacies; direct dealing on the platform will lead to improved margins. And consumers will undoubtedly welcome the platform’s price discovery capabilities. The Trxade digital pharmaceutical exchange is set to shakeup the staid drug distribution business.

Trxade’s web-based platform has something for everyone. Patients will benefit from the lower prices its algorithms identify, while pharmacies are now more likely to avoid negative reimbursement costs, which flatten profit margins. Close to half the number of independent pharmacies operating across the nation are registered users on the Trxade platform. The company expects 2019’s signup rate—8 or 9 new pharmacies every day—to continue throughout 2020. There is good reason for those expectations. For a long time, America’s independent pharmacies haven’t been getting a good deal.

The U.S. pharmaceutical industry is a sprawling system made up of around 65,000 pharmacies. Most are branches of the large chains. A recent report provides a snapshot of the landscape (http://ibn.fm/cfPqA). CVS Pharmacy, the largest, employs 18,631 pharmacists in close to 9,105 stores. Walgreens has 17,437 pharmacists working in its 7,713 or so stores, while Rite Aid with its 4,515 stores employs 9,194 pharmacists. Walmart has less stores (4,403) than Rite Aid but employs more pharmacists (10,458). This colossal operation moves around $330 billion worth of pharmaceuticals per annum. But most of the business goes to the giant chains with their thousands of retail outlets and their ability to capture significant excess margin at the cost of the consumer, employers and government.

This leaves about one-third of the nation’s pharmacies that are run independently, that do not belong to a large corporate chain. These smaller independent pharmacies tend, on average, to be $3.5 million-per-annum enterprises owned and managed, typically, owner operated vocational pharmacists. Predictably, they struggle to stay afloat, surviving on thin margins that continuously pose an existential threat.

The presence of pharmacy benefit managers (“PBMs”) hasn’t really helped. These third party administrators of prescription drug programs were expected to reduce the purchase costs of drugs across the board and they have but the benefits have accrued to a select few. The three largest PBMs— Caremark (CVS Health) / Aetna, Express Scripts, OptumRx (UnitedHealth)—now control 76 percent of the market. And, as the Brookings Institution has pointed out in testimony to Congress, “health care markets are becoming more consolidated, causing price increases for purchasers of health services…” (http://ibn.fm/LeLbP).

However, Trxade’s pharmaceutical platform gives independent pharmacies a real shot at reducing their purchasing costs, and much more. The integrated pharmaceutical services company offers not just a web-based purchasing platform for transactions between independent pharmacists and drug distributors (“B2B”), but a network of associated pharmacies with its E-Hub software, and a mail order pharmacy, as well as warehouse and drug delivery services.

Called the Trxade Exchange, the platform gives small pharmacies access to the wider pharmaceutical distribution network, allowing them to search for and view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. Trxade is hoping that the majority of America’s 24,000 independent pharmacies, who which together have a combined annual purchasing power of over $92 billion, will eventually see how Trxade’s supportive platform that can make their businesses more profitable.

For more information, visit the company’s website at www.TrxadeGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

• ISWH CEO reports strong organic growth in home healthcare division
• Company “most excited” about revolutionary solution designed to provide home-health patients with simple, one-button, wearable device to summon help
• TeleCare allows patients to maintain greatest level of independent existence while still accessing care they need

ISW Holdings (OTC: ISWH), a brand-management portfolio company with diverse partnerships, looks to be particularly astute at recognizing growing businesses in multiple sectors. The company has partnerships in crypto mining, renewable energy, wellness and restoration, and the adult-beverage industry, as well as early-stage operations in supply chain and logistics management. Most recently, the company has announced it is launching its proprietary telecare technology service as part of its successful and growing home healthcare business (http://ibn.fm/I8mHJ).

Noting that the company is making tremendous strides toward integrating telehealth services into its home healthcare division — Paradigm Home Health — ISWH president and chairman Alonzo Pierce reported strong organic growth in the space, “with sequential monthly topline expansion in place now for five consecutive quarters and counting.”

“Our TeleCare service is one of the initiatives we are most excited about right now,” he continued in a letter to ISWH shareholders. “This is a new technology solution we are preparing to launch as part of our home healthcare service. TeleCare is a revolutionary technology solution designed to provide home-health patients with a simple, one-button wearable device to quickly and easily summon a visiting nurse, home-health provider, or 24/7 nurse-assist hot line anytime medical assistance is urgently needed.”

The technology works like a nurse-call button in a hospital. “Our research suggests this will create tremendous additional value and enhance our clients’ lives by helping them to maintain the greatest possible level of independent existence while still having access to the supportive care they need,” Pierce observed.

The timing for the technology releases looks to be ideal. ISW Holdings is introducing the technology solution in the wake of recent steps taken at the federal level to deregulate telehealth in response to the COVID-19 pandemic health crisis. “Our sense is that this new strong momentum towards telehealth solutions is going to be sticky,” Pierce said. “In other words, the pandemic spurred a transition, and it’s going to be impossible to put the genie back in the bottle afterwards. Companies that fail to embrace the future risk being left behind.”

Recognizing possibilities and embracing opportunity is at the heart of what ISWH is about. This newest move is part of the company’s overarching strategy to create companies and partnerships in disruptive industries. The use of innovative products and services is key to anticipating the future needs of the markets in which the company serves. “ISW is determined to embrace new solutions and implement more efficient and effective strategies to provide our clients, customers, and shareholders with every inch of edge we can muster,” Pierce concluded. “And our new TeleCare solution exemplifies that determination.”

For more information, visit the company’s website at www.ISWHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to ISWH are available in the company’s newsroom at http://ibn.fm/ISWH

• PowerBand Solutions subsidiary MUSA Auto Finance, LLC, has secured an agreement with a national depository financial institution that provides the online auto leasing platform with $300 million for transactions
• PowerBand Solutions is building an innovative smart tech platform that streamlines the transfer of money and paperwork associated with financing and inventory, vehicle inspections and auction negotiations
• The remote-access tech solution provides a timely response to the COVID-19 pandemic, which has been responsible for governmental policies worldwide restricting in-person group gatherings
• Despite the reach of the pandemic, Americans’ desire for getting out on the country’s roads during the summer remains high, with some 700 million trips forecast during the season, 97 percent of which would be by automobile

Disruptive fintech innovator PowerBand Solutions (TSX.V: PBX) (OTCQB: PWWBF) (FRA: 1ZVA) announced July 13 that its U.S. leasing division, MUSA Auto Finance, LLC, have begun originating auto loans in Texas and Florida and will soon add California and other states’ markets after gaining $300 million in lease financing from a federally chartered U.S. depository financial institution for its online leasing platform (http://ibn.fm/O9wIq).

The $300-million funding agreement with the national financial institution opens the door for PowerBand to expand its future lending facilities, allowing customers and dealers to use their smart phones or other digital devices to buy, lease, and finance vehicles on PowerBand’s innovative new platform as easily as they buy products through web-based retailers such as Amazon.

The AAA 2020 Summer Forecast Report issued recently by the renowned auto club group predicted that Americans would take 700 million trips this summer, 97 percent of which would be by car due to low gasoline prices and lingering wariness of the shared confines inherent in plane travel. “You have that comfort of being in your own vehicle,” Mark Jenkins, spokesman for AAA, stated in a Tampa Bay Times report (http://ibn.fm/stndu). “You know how clean it is, and you know who you’re traveling with.”

National unemployment rates have remained in the double digits even though they have declined from their April peak of 14.7 percent, representing nearly 18 million people who may have more than the usual amount of free time on their hands while buoyed by pandemic-inspired national economic stimulus programs (http://ibn.fm/h5IV8).

The auto loans launching under PowerBand Solutions’ subsidiary are providing Americans with timely solutions for their driving and financing needs amid the pandemic as an alternative to physical in-person purchasing. MUSA’s platform calculates a lease on a loan application, uses AI functions to automatically render a decision on the application and provides approval to dealer partners when applicable, profiling the lease contract in the process. Approvals can occur in seconds.

“Our strategy is to aggregate further funding facilities in the weeks and months ahead, to offer multi-billion-dollar financing opportunities to consumers and dealers using our platform in the United States and Canada,” PowerBand CEO Kelly Jennings stated in the announcement. “We are looking forward to finally offering our products to our many partners in the automotive sector and millions of consumers in the coming months across North America.”

PowerBand Solutions’ platform streamlines not only the transfer of money and paperwork associated with financing, but also inventory paperwork, vehicle inspections and auction negotiations — all without requiring direct in-person contact that might put a buyer or seller at risk of infection while the pandemic’s transmission rate remains high.

The pandemic’s lasting effect on the economy has yet to be fully calculated, but even if infection rates continue to rise once North America descends into a colder winter season appliances and generally essential goods such as automobiles are likely to remain in demand (http://ibn.fm/1olBD).

PowerBand’s platform is a forward-thinking solution that expects to distinguish itself as an example of American innovation in business during the most difficult of market conditions. MUSA was awarded a contract by Tesla Motors to become a national leasing partner in 2018 as a show of confidence in MUSA’s proprietary technology.

For more information, visit the company’s website at www.PowerBandSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to PWWBF are available in the company’s newsroom at http://ibn.fm/PWWBF

• Clinical studies show serotonergic psychedelics may be effective in treating anxiety, depression, addiction and more
• Interest in serotonergic psychedelics has dramatically increased within last decade
• Cybin Corp. is focused on furthering research, development of psilocybin-based medications through Serenity Life Sciences Inc.

For decades seen as a taboo substance, psychedelics today are being viewed in a powerful new light. This significant societal switch is based, at least in part, on credible clinical studies, which have shown that serotonergic psychedelics may be effective in treating anxiety, depression, addiction and even cancer (http://ibn.fm/mSzY5). Cybin Corp., a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products as well as the functional mushroom market, appears to be a strong player in this developing new space.

“Scientific interest in serotonergic psychedelics . . . has dramatically increased within the last decade,” reported a recent article published by the American Society for Clinical Pharmacology and Therapeutics. “Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depression, as well as addiction to tobacco and alcohol. Moreover, recent research has suggested that these compounds have potential efficacy against inflammatory diseases through novel mechanisms, with potential advantages over existing antiinflammatory agents. . . .

“Antiinflammatory effects may hold promise for efficacy in treatment of inflammation-related nonpsychiatric as well as potentially for psychiatric disorders,” the article, which was titled “Psychedelics as Medicines: An Emerging New Paradigm,” stated. “Serotonergic psychedelics operate through unique mechanisms that show promising effects for a variety of intractable, debilitating, and lethal disorders, and should be rigorously researched.”

This research has fueled growth in an industry based on psychedelic medication, a space where Cybin Corp. is emerging as a leader. The company is focused on furthering research and development of psilocybin-based medications through its wholly owned division, Serenity Life Sciences Inc. Psilocybin is a naturally occurring, non-habit-forming psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.

Cybin is committed to its mission of bringing “fungi-derived psychedelic and medicinal products into the world that may potentially drive the next discovery phase of life-changing medications to treat mental illness and other health conditions.” With that mission in mind, Cybin also has a wholly owned division, called Journey Inc. that offers branded, proprietary products targeting mental wellness, the immune system, detoxification and overall general health and wellness.

Cybin is a mushroom life-sciences company advancing psychedelic and nutraceutical-based products. Cybin is launching psilocybin-based products in jurisdictions where the substance is not banned. Simultaneously, Cybin is structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin

• Deltec recently released investment research concerning COVID-19-related U.S. stimulus package
• Company’s combined expertise comprises more than 150 professionals, including private bankers, certified public accountants, investment advisors, lawyers, trust officers
• Deltec recently recognized as ‘Best Private Bank in the Caribbean 2020’ by Global Banking and Finance Review

As a leading financial hub for the global investment, finance and entrepreneur community, Deltec Bank & Trust offers specialized financial solutions and institutional expertise with the primary goal of creating opportunities for its clients to enhance their wealth. As part of its service offerings, the company recently released a special report (http://ibn.fm/7Ig6O) outlining details of the U.S. government’s $2.2 trillion Coronavirus Aid, Relief, and Economic Security (“CARES”) stimulus package. The timely piece includes commentary concerning the potential effects to US personal incomes should the unemployment insurance benefits be allowed to expire at the end of the month without extension.

Besides offering specialized services that span private, corporate and merchant banking, Deltec moves beyond its core set of services by providing specialized research reports published periodically for the benefit of its clients.

Forming part of Deltec’s global financial hub is the collective experience of more than 150 professionals gleaned from a wide array of backgrounds, including private bankers, certified public accountants, investment advisors, lawyers and trust officers. With the power of their combined experience from some of the world’s largest and most prestigious financial institutions, the professionals at Deltec provide unparalleled expertise in working with complex multi-jurisdictional entities in addition to individuals and families aiming to protect their wealth. The company’s assets under management, administration and custody have risen substantially as a result of the purchase of Société Generale’s private banking business in The Bahamas, growing to over $12 billion as of late 2019 (http://ibn.fm/lZTrN).

Recognized periodically for its outstanding performance and achievements, Deltec recently won the ‘Best Private Bank in the Caribbean 2020’ award for a second time from the Global Banking and Finance Review (http://ibn.fm/s724h). Besides being recognized internationally for strong client relations and highly personalized innovative products, Deltec maintains a strong position at the forefront of the digital banking and fintech revolution with its annual conference focused on disruptive technologies within the financial services industry (http://ibn.fm/BdQSA).

Founded in 1959, Deltec Bank & Trust Ltd. is the flagship company of the Deltec International Group, a diversified independent financial services organization that provides a wide range of financial services that include investment management and research, fund administration, merchant banking, corporate advisory, digital asset solutions and global insurance. Besides providing top-tier services for their diverse range of clientele, Deltec also actively engages with the local community in The Bahamas through its Deltec Initiatives Foundation that aims to empower youth in driving forward positive social impact through the power of the arts, entrepreneurship and education.

For more information, visit the company’s website at www.DeltecBank.com.

NOTE TO INVESTORS: The latest news and updates relating to Deltec are available in the company’s newsroom at http://ibn.fm/Deltec

• Pharmaceutical and health care services company Trxade Group has added new tools to its Bonum Health telemedicine platform that will help patients better inform themselves about their medical needs and their provider’s prescription recommendations
• Trxade Group operates a B2B pharmaceutical network that supports independent, neighborhood-based healthcare businesses with up-to-the-minute information on drug pricing
• The company also assists patients on a B2C basis through its subsidiaries that include Bonum Health’s telemedicine platform and Delivmeds’ pharmaceutical delivery service
• Trxade Group’s development of remote-access medical care during the past two years has proven timely in the face of restrictions on gatherings imposed during the novel coronavirus pandemic
• The company has been increasing its profile among investors with uplisting to the Nasdaq exchange and entry to the annual Russell’s Microcap Index

Growing health services provider Trxade Group (NASDAQ: MEDS) recently announced the expansion of its patient empowerment telehealth platform Bonum Health, which has added access to educational resources that can help better understand and direct their care management. Trxade Group’s wholly owned mobile telehealth application will now link to the Merck Manual, a standard reference guide for physicians since 1899, according to the announcement. The company’s intent in further developing the Bonum Health app is to “encourage, enable, and empower patients” with information pertinent to their medical needs and provider’s drug recommendations. Trxade Group has been undergoing significant portfolio development during recent months. The company’s mission is to help sustain independent, locally owned community pharmacies, and two years ago it boosted its own capacity to reach consumers directly when it acquired accredited Internet pharmaceutical Community Specialty Pharmacy, LLC (http://ibn.fm/Y0xaU) and launched its consumer-based medication delivery app Delivmeds.com. Trxade Group has since added its Bonum Health Hub telehealth service as a means for patients and providers to consult using mobile smart tech without a need for in-office visits. The secure, privacy-enabled technology has proven particularly timely during a year when a novel coronavirus reached pandemic-level global transmission and spurred health and government leaders to enact varied restrictions against group gatherings (http://ibn.fm/lCYCQ). Trxade Group has this year seen its operation uplisted to the Nasdaq exchange as it has gathered funding, and last month it gained inclusion on this year’s Russell’s Microcap Index. “This marks an exciting capital markets milestone in the growth and trajectory of our company as we continue to execute upon our growth strategy and raise awareness about the Company throughout the investment community,” Trxade Chairman and CEO Suren Ajjarapu stated in a news release at the time (http://ibn.fm/7qjoH). Trxade Group’s eBay-type B2B business model significantly lowers prescription drug costs, in part due to its emphasis on transparency. At the same time, the company’s revenues grew 94 percent during 2019 as a result of fee income for medications listed on the company’s web-based market platform (http://ibn.fm/U20h6) and 11,400 independent pharmacies became new subscribers to the company’s platform for analyzing drug pricing on an up-to-the-minute basis. For more information, visit the company’s website at www.TrxadeGroup.com. NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

• SRAX’s Sequire platform has grown to 75 publicly traded companies comprising 500,000+ active investors
• Sequire’s sales exceeded $2.5 million in Q2 2020 with additional $3 million expected to close in Q3
• Platform expansion set to follow definitive securities purchase agreement worth $13 million

With the importance of big data on the rise, it should come as no surprise that the finance industry is leveraging the use of data analytics to deliver increased transparency and improve communications with stakeholders on every level. SRAX (NASDAQ: SRAX), a digital marketing and consumer data management technology company, is leveraging this trend through Sequire, its innovative investor intelligence platform. Through the use of proprietary technology, Sequire unlocks big data analytics in powerful new ways that connect public companies with traders and long-term investors for communication and marketing campaigns.

Interactions between public companies, shareholders and future prospects are becoming increasingly complex, requiring innovative new strategies and creative solutions that only big data can provide. Sequire facilitates these communications through an online platform that allows public companies to monitor the activities of current investors, activate campaigns to engage existing shareholders and create marketing campaigns to attract new investment to the company.

Sequire’s success – despite the effect of COVID-19 lockdowns – has been significant so far in 2020, growing to 75 publicly-traded companies comprising 500,000+ active investors and traders with sales exceeding $2.5 million in Q2 2020 (http://ibn.fm/Z6LGF). Expansion of the platform is imminent following recent news that the Company has entered into a definitive securities purchase agreement led by existing institutional investors for the purchase and sale of $13 million senior secured convertible debentures to fund a rapid expansion of the platform (http://ibn.fm/4zZla).

“On Thursday, we announced a capital raise of $13 million, which we will use in part to fund the rapid expansion of Sequire,” said SRAX CEO and founder Christopher Miglino (http://ibn.fm/4d3g5). “Our clients have seen notable results from the platform and its related services. We’ve also seen a significant increase in the number of clients on the platform with Q2 sales hitting over $2.5 million and an additional $3 million in the pipeline, with a very high probability of closing in Q3.”

Along with Sequire, SRAX delivers a suite of specialized tools for other industries, delivering a digital competitive advantage for brands in the CPG, luxury goods and lifestyle verticals by integrating all aspects of the advertising experience into one platform. At a time when consumers are becoming increasingly aware of the value of their data, SRAX is more than several steps ahead with the company’s BIGtoken platform, comprising over 16 million users and providing them with compensation for their data while simultaneously creating reliable data sets that can be accessed by marketers for a fee.

New, innovative and creative uses of big data are increasingly being used to meet the demands of businesses looking to survive the current economic period. SRAX’s services meet this demand by giving clients the ability to target and access specific niche groups across 25,000 unique points of segmentation, providing a much-needed strategic edge to businesses of all types across almost every industry.

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• POAI improved liquidity position, streamlined capital structure with conversion of $2.1 million convertible note
• Business highlights include continued initial study to sequence ovarian tumors, validate “reach-back”
• Company closed transaction resulting in gross cash proceeds of approximately $2.2 million

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced Q1 2020 financial results and business highlights (http://ibn.fm/mFwpq) as well as receipt of cash proceeds of $2.2 million from exercise of warrants (http://ibn.fm/2n6x5).

“[POAI] improved our liquidity position and streamlined our capital structure with the conversion of a $2.1 million convertible note, previously held by me, to newly issued equity,” said POAI CEO Dr. Carl Schwartz. “This action demonstrates my confidence in the commercial viability of our work, and when combined with the additional capital we raised through an equity offering, provides us with the cash runway to fund key clinical, regulatory and operational milestones for the next several quarters. In addition, we have significantly reduced the corporate structure of our Skyline Medical business to enable it to operate independently as we consider strategic alternatives for this business.”

According to Predictive Oncology’s report, for the quarter ended March 31, 2020, company revenues increased to $295,943 compared with $255,241 for the first quarter of 2019. Gross margins remained strong at 69% for the same period, compared with 71% in the 2019 period. Other Q1 highlights included the following:

• Continued initial study to sequence ovarian tumors and validate “reach-back” process; study is on schedule to be completed Q3 2020
• Signed LOI to acquire Quantitative Medicine, a biomedical analytics and computational biology company; closed early July Q3 2020
• Signed a term sheet to acquire both BioDtech and Soluble Therapeutics and its HSC(TM) Technology; closed in Q2 2020

In addition, POAI announced the closing of a previously announced transaction resulting in gross cash proceeds of approximately $2.2 million paid to the company, prior to deducting placement agent fees and offering expenses, through the exercise of certain existing warrants by several holders to purchase an aggregate of up to 1,396,826 shares of common stock at an exercise price of $1.575 per share. The shares of common stock issued upon exercise of the existing warrants are registered for resale pursuant to a registration statement on Form S-1.

In consideration for the immediate exercise of the existing warrants for cash, the exercising holders received new unregistered warrants to purchase up to an aggregate of 1,396,826 shares of common stock at an exercise price of $1.80 per share with an exercise period of five and one-half years from the issuing date. Predictive Oncology plans to use these funds for working capital and general corporate purposes.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through the company’s Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is utilizing artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI